Jerica Gu
Clinical Trial Physician, Pulmonology Bristol Myers Squibb
Seminars
Wednesday 30th September 2026
Targeting the LPA1 Pathway in IPF: Phase 3 Insights from the ALOFT-IPF Program Evaluating Admilparant
9:00 am
- Presenting clinical insights from the Phase 3 ALOFT-IPF trial evaluating admilparant (BMS-986278), an oral lysophosphatidic acid receptor-1 (LPA1) antagonist, including its effect on lung function decline and disease progression in idiopathic pulmonary fibrosis
- Exploring the biological rationale for targeting LPA1 signaling in pulmonary fibrosis, including its role in fibroblast recruitment, activation, and extracellular matrix deposition that drives progressive lung scarring
- Discussing how emerging Phase 3 results may shape the evolving treatment landscape in IPF, including positioning alongside existing antifibrotics and implications for future combination therapy strategies
